[177Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial.

Saved in:
Bibliographic Details
Title: [177Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial.
Authors: Baudin E; Department of Imaging, Endocrine Oncology Unit, Gustave Roussy, University Paris Saclay, Villejuif, France. Electronic address: eric.baudin@gustaveroussy.fr., Durand A; Department of Medical Oncology, Edouard Herriot Hospital, Hospices Civils de Lyon, University of Lyon, Lyon, France., Beron A; Department of Nuclear Medicine, Huriez Hospital, University of Lille, Lille, France., Smith D; Department of Gastroenterology, Haut-Lévèque Hospital, University of Bordeaux, Bordeaux, France., Déandreis D; Department of Imaging, Nuclear Medicine Unit, Gustave Roussy, University Paris Saclay, Villejuif, France., Taieb D; Department of Nuclear Medicine, La Timone Hospital, Aix-Marseille University, Marseille, France., Ansquer C; Department of Nuclear Medicine, Hôtel Dieu Hospital Center, University of Nantes, Nantes, France., Dierickx L; Department of Nuclear Medicine, Oncopole Claudius Regaud, IUCT-Oncopole, University of Toulouse, Toulouse, France., Deshayes E; Department of Nuclear Medicine, Montpellier Cancer Institute, University of Montpellier, Montpellier, France., Hentic O; Department of Pancreatology and Digestive Oncology, Beaujon Hospital, University of Paris-Cité, Clichy, France., Moalla S; Department of Imaging, Gustave Roussy, University Paris Saclay, Villejuif, France., Menu Y; Department of Imaging, Gustave Roussy, University Paris Saclay, Villejuif, France., Lebtahi R; Department of Nuclear Medicine, Beaujon Hospital, University of Paris-Cité, Clichy, France., Assenat E; Department of Medical Oncology, CHU Montpellier, Montpellier, France., Touchefeu Y; Department of Digestive Disease, Hôtel Dieu Hospital Center, University of Nantes, Nantes, France., Guimbaud R; Department of Digestive Medical Oncology, Toulouse Hospital, CHU de Toulouse, Toulouse, France., Dahan L; Department of Digestive Oncology, La Timone Hospital, University of Marseille, Marseille, France., Lamartina L; Department of Imaging, Endocrine Oncology Unit, Gustave Roussy, University Paris Saclay, Villejuif, France., Cheurfa N; Office of Biostatistics and Epidemiology, Gustave Roussy, University Paris Saclay, Villejuif, France., Quak E; Department of Nuclear Medicine, François Baclesse Center, Caen, France., Bouhier-Leporrier K; Department of Gastroenterology, Caen Hospital, CHU Caen, Caen, France., Haissaguerre M; Department of Endocrinology, Bordeaux Hospital, University of Bordeaux, Bordeaux, France., Hindie E; Department of Nuclear Medicine, Bordeaux Hospital, University of Bordeaux, Bordeaux, France., Cao CD; Department of Endocrinology, Huriez Hospital, CHU Lille, Lille, France., Lombard-Bohas C; Department of Medical Oncology, Edouard Herriot Hospital, Hospices Civils de Lyon, University of Lyon, Lyon, France., Jannin A; Department of Endocrinology, Huriez Hospital, CHU Lille, Lille, France., Walter T; Department of Medical Oncology, Edouard Herriot Hospital, Hospices Civils de Lyon, University of Lyon, Lyon, France., Ducreux M; Department of Medical Oncology, Gustave Roussy, University Paris Saclay, Villejuif, France., Chaib S; Department of Pharmacy, Radiopharmacy, L Pradel Hospital, Hospices Civils de Lyon, University of Lyon, Lyon, France; Lyon Cancer Research Center, CNRS, INSERM, Lyon, France., Hadoux J; Department of Imaging, Endocrine Oncology Unit, Gustave Roussy, University Paris Saclay, Villejuif, France., Foulon S; Office of Biostatistics and Epidemiology, Gustave Roussy, University Paris Saclay, Villejuif, France; Inserm, University Paris-Saclay, CESP U1018, Oncostat, labeled Ligue Contre le Cancer, Villejuif, France.
Source: The Lancet. Oncology [Lancet Oncol] 2026 Jun; Vol. 27 (6), pp. 699-710.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study; Comparative Study
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-5488
DOI:10.1016/S1470-2045(26)00108-7